neoSurgical bid the sunny season adieu by opening an American headquarters in Chicago, Ill., and debuting a new medical device for minimally invasive and laparoscopic surgery. The international firm claims its flagship product, neoClose, "revolutionizes" the closure of port or access sites in the abdominal wall after keyhole surgery. Current methods to close port or access sites requires significant skill and does not consistently result in positive patient outcomes; surgeons have continually grappled with locating sutures within the abdomen as well as managing post-operative issues such as pain and herniation, company executives claim.
The neoClose device consists of an AccuGuide that helps accurately deliver a bio-absorbable PGA suture and attached bio-absorbable AutoAnchor using the trocar as the reference point. The system, which swiftly and easily closes wounds, can be deployed under full pneumo/inflation in three simple steps in less than one minute.
"We're very excited to announce the news of our U.S. office in Chicago and to be debuting neoClose," said Barry Russell, neoSurgical founder and CEO. "Overcoming challenges with innovative technology that makes surgical procedures simpler, faster and more efficient is our main focus. In fact, feedback from surgeons in response to neoClose has been '... it's so simple, why didn't I think of that!' Conceiving and developing devices that work more simply than current options is at the kernel of what we do. It is always more challenging to engineer a device to the point where everyone who handles it sees the benefits and appreciates the simplicity."
Initially launched in Europe, neoClose is approved by the U.S. Food and Drug Administration and commercially available to surgeons in the United States.
neoSurgical is a global medical device company that develops laparoscopic and minimally-invasive surgical devices. The firm is based in Dublin, Ireland.